Clinical Trial Update: Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating bevacizumab with or without TRC105 in metastatic kidney cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma
• Renal Cell Cancer
• Renal Cell Carcinoma
• Type 2 Papillary Renal Cell Carcinoma
• Type Papillary Renal Cell Carcinoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• TRC105 (carotuximab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2018-06-26